In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
201 News Items found
MSK researcher in a lab
MSK Research Highlights, August 24, 2023

New MSK research suggests a method for revealing DNA repair “scars” could help make treatment decisions in BRCA1- and BRCA2-deficient cancers; modified a bacteria-made compound to target mutant KRAS-driven cancers; and shed new light on brain metastasis in non-small cell lung cancer.
Close up of an MSK researcher's hands and arms handling test tubes in the lab.
Gerstner Sloan Kettering Graduate Students Receive 2024-2025 Fellowships

Nine GSK PhD students were awarded competitive fellowships from prestigious external agencies such as the National Cancer Institute (NCI) and National Science Foundation (NSF).
Dr. Joan Massagué, Sloan Kettering Institute Director received the Pezcoller Foundation-AACR International Award for Cancer Research and was named an AACR fellow at AACR16.
Announcement
News from #AACR16: Targeted Therapy Breakthrough, Improved Survival in Melanoma, and Benefits of Gut Bugs

Long-awaited results of clinical trials testing targeted drugs and immunotherapy combinations were on offer at the annual American Association for Cancer Research (AACR) conference.
Cracking a Code: Landmark Prospective Study Helps Researchers Better Understand Which MGUS Patients Will Progress to a Multiple Myeloma Diagnosis

Memorial Sloan Kettering Cancer Center (MSK) researchers published new results that found that individuals with low-risk or intermediate-risk myeloma precursor disease known as monoclonal gammopathy of undetermined significance (MGUS) can convert to high-risk MGUS and progress to multiple myeloma within a five-year window. This research clinically supports recommendations for annual blood tests for all individuals diagnosed with MGUS along with re-assessments of a patient’s clinical-risk status. Their research was published today online in <i>JAMA Oncology</i>.
Reicy Bobadilla stands in front of a window with the MSK logo on it
What You Should Know About Mesothelioma in Younger Patients

A new study is challenging the perception that mesothelioma affects only older men. Learn why MSK experts say the medical community should be aware of this rare cancer's early symptoms.
Nitya Raj
6 Tips for a Successful Telemedicine Visit with Your Doctor

Learn the keys to a successful telemedicine visit from a cancer specialist at Memorial Sloan Kettering.
Nadeem Riaz (left) and Jorge Reis-Filho (right)
For People with Certain BRCA Mutations, Activating the Immune System Could Be Promising Treatment

Human data and results from mouse experiments suggest that people with BRCA2 mutations may respond well to immunotherapy drugs.
A researcher working in an MSK lab
MSK Research Highlights, April 23, 2025

New MSK research identifies a rare cell population responsible for AML persistence and resistance to therapy; sheds new light on early brain development; and investigates how other health conditions can increase cancer risk in midlife. MSK clinical trials also supported the recent approval of the targeted drug larotrectinib by the FDA.
Stephen Sternberg
Remembering Stephen Sternberg, a Respected and Influential Surgical Pathologist

Memorial Sloan Kettering is sad to note the passing on May 12 of Stephen Sternberg, at the age of 100. Dr. Sternberg spent his entire career at MSK as a surgical pathologist. Widely known as a leader in the field of pathology and highly regarded for his expertise, he was also greatly respected as an editor of major national publications, which garnered him a broad, devoted following around the world.
MSK patient Jason Giani holding a Valentine's Day card
Feature
Sharing Love at MSK — One Card at a Time

Cards are a longstanding Valentine’s tradition — and The Scarlett Fund, with help from Memorial Sloan Kettering Cancer Center employees, is using cards to make sure that patients and staff will be feeling the love for a long time to come.